Clinical Trial Update: A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 [Phase 1]

View source ↗

Summary

Phase I dose-escalation study evaluating the safety and biological activity of recombinant human interleukin-18 in Non-Hodgkin lymphoma; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Recombinant human interleukin-18 (interleukin-18)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Non-Hodgkin | Phase 1 | Status: COMPLETED